Novartis has received accelerated approval from the U.S. Food and Drug Administration (FDA) for Vanrafia (atrasentan), a highly selective endothelin A (ETA) receptor blocker designed to lower proteinuria in individuals with primary immunoglobulin A nephropathy (IgAN). This medication serves as an additional therapy to standard supportive care and does not require a Risk Evaluation and Mitigation Strategy (REMS) program. A Phase III clinical trial demonstrated that atrasentan
